Significance of MMP-9 expression and MMP-9 polymorphism in prostate cancer

Tumori

Volumn 99, Issue 4, 2013, Pages 523-529

  Schveigert, Diana ^a   Valuckas, Konstantinas Povilas ^a   Kovalcis, Viktorija ^a   Ulys, Albertas ^a   Chvatovic, Genovefa ^a   Didziapetriene, Janina ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

Author keywords

MMP 9 expression; Polymorphism; Prostate cancer

Indexed keywords

GELATINASE B;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MMP 9 GENE; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84890879111     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161309900414     Document Type: Article

References (28)

1. GLOBOCAN data [Internet]. Available at http://globocan.iarc.fr
2. Shariat SF, Karam JA, Roehrborn CG: Blood biomarkers for prostate cancer detection and prognosis. Future Oncol, 3: 449-461, 2007.
3. Rao AR, Motiwala HG, Karim O: The discovery of prostatespecific antigen. BJU Int, 101: 5-10, 2007.
4. Leman ES, Getzenberg RH: Biomarkers for prostate cancer. J Cell Biochem, 108: 3-9, 2009.
5. Prior C, Guillen-Grima F, Robles JE, Rosell D, Fernandez-Montero JM, Agirre X, Catena R, Calvo A: Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J Urol, 28: 681-686, 2010.
6. Noel A, Jost M, Maquoi E: Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol, 19: 52-60, 2008.
7. Pulukuri SM, Rao JS: Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol, 32: 757-765, 2008.
8. O'Mara TA, Clements JA, Spurdle AB: The use of predictive or prognostic genetic biomarkers in endometrial and other hormone-related cancers: justification for extensive candidate gene single nucleotide polymorphism studies of the matrix metalloproteinase family and their inhibitors. Cancer Epidemiol Biomarkers Prev, 18: 2352-2365, 2009.
9. Escaff S, Fernandez JM, Gonzalez LO, Suarez A, Gonzalez-Reyes S, Gonzalez JM, Vizoso FJ: Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer, 102: 922-929, 2010.
10. Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, Di Trapani D, Gebbia N, Leto G: MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res, 27: 1519-1525, 2007.
11. Sauer CG, Kappeler A, Spath M, Kaden JJ, Michel MS, Mayer D, Bleyl U, Grobholz R: Expression and activity of matrix metalloproteinases -2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Arch, 444: 518-526, 2004.
12. Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D, Moses MA: Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res, 14: 6610-6617, 2008.
13. Gil Ugarteburu R, Rivas del Fresno M, Gonzalez Rodriguez I, Gonzales Arriaga P, Lopez Cima F, Fernandez Samoano A, Fernandez Garcia I, Benito Garcia P, Muruamendiaraz Fernandez V, Tardon A: Matrix metalloproteinase-9 polymorphisms in the diagnosis of prostate cancer. A preliminary experience. Arch Esp Urol, 63: 125-132, 2010.
14. Sfar S, Saad H, Mosbah F, Gabbouj S, Chouchane L: TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet Cytogenet, 172: 38-44, 2007.
15. th edition. Sobin L, Gospodarowicz M, Wittekind C (Eds), p 336, UICC: Wiley-Blackwell Press, 2009.
16. Di Carlo A, Mariano A, Terracciano D, Ferro M, Montanaro V, Marsicano M, Di Lorenzo G, Altieri V, Macchia V: Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients. Oncol Rep, 24: 3-8, 2010.
17. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, Travali S, Stivala F, Canevari S, Libra M: Activation of the osteopontin/matrix metallopro-teinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res, 14: 7470-7480, 2008.
18. Shah SA, Spinale FG, Ikonomidis JS, Stroud RE, Chang EI, Reed CE: Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Cardiovasc Surg, 139: 984-990, 2010.
19. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O: Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer, 95: 1902-1910, 2002.
20. Gonzalez LO, Pidal I, Junquera S, Corte MD, Vazquez J, Rodriguez JC, Lamelas ML, Merino AM, Garcia-Muniz JL, Vizoso J: Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer, 97: 957-963, 2007.
21. Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA, Mazzarino C: Uterine cervical carcinoma: role of matrix metalloproteinases (Review). Int J Oncol, 34: 897-903, 2009.
22. Sullu Y, Demirag GG, Yildirim A, Karagoz F, Kandemir B: Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract, 207: 747-753, 2011.
23. Offersen BV, Knap MM, Horsman MR, Verheijen J, Hanemaaijer R, Overgaard J: Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta Oncol, 49: 1283-1287, 2010.
24. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, Mazzarino MC: Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res, 33: 44-50, 2005.
25. Smolarz B, Szyllo K, Romanowicz-Makowska H, Niewimdomski M, Kozlowska E, Kulig A: PCR analysis of matrix metalloproteinase 3 (MMP-3) gene promoter polymorphism in ovarian cancer. Pol J Pathol, 54: 233-238, 2003.
26. Dos Reis ST, Villanova FE, de Andrade PM, Pontes J, Silva IA, Canavez FC, Sanudo A, Srougi M, Leite KR: Polymorphisms of the matrix metalloproteinases associated with prostate cancer. Mol Med Report, 1: 517-520, 2008.
27. Rollin J, Regina S, Vourc'h P, Iochmann S, Blechet C, Reverdiau P, Gruel Y: Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer, 56: 273-280, 2007.
28. Xing LL, Wang ZN, Jiang L, Zhang Y, Xu Y-Y, Li J, Luo Y, Zhang X: Matrix metalloproteinase-9-1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. World J Gastroenterol, 13: 4626-4629, 2007.